Ma Honglian, Peng Fang, Xu Yujin, Bao Yong, Hu Xiao, Wang Jin, Fang Min, Kong Yue, Dong Baiqiang, Chen Ming
The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer, Chinese Academy of Sciences, Hangzhou, China.
Department of Radiation Oncology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Ann Palliat Med. 2021 Jul;10(7):7560-7570. doi: 10.21037/apm-21-1092.
A prospective phase II study showed that Endostar combined with concurrent chemoradiotherapy (CCRT) can improve overall survival (OS) in patients with inoperable locally advanced non-small cell lung cancer (NSCLC). This study aimed to retrospectively compare the 5-year survival rates of patients with inoperable locally advanced NSCLC who received a combination of Endostar and CCRT to that of patients receiving CCRT.
Treatment-naive patients with inoperable locally advanced NSCLC who had long-term follow-up data were included in this study. Patients in CCRT + Endostar group were treated with Endostar plus radical CCRT, and patients in CCRT group received radical CCRT. For patients with a radiation dose ≥60 Gy, Kaplan-Meier method was used for survival analysis, and Cox proportional-hazards regression model was used for univariate analysis.
A total of 104 participants were included in the CCRT + Endostar group with 89 participants included in the CCRT group. There were 88 (84.6%) and 74 (83.1%) male patients, respectively. The median follow-up times of two groups were 73.6 (95% CI: 65.6 to 81.7 months) and 66.3 months (95% CI: 52.7 to 79.9 months), respectively. The median overall survival (OS) was 29.7 (95% CI: 22.8 to 36.6 months) and 21.3 months (95% CI: 15.9 to 26.7 months), respectively.
This study showed that the 5-year survival of those patients who received the combination treatment of Endostar and radical CCRT was significantly superior to those who received radical CCRT.
一项前瞻性II期研究表明，恩度联合同步放化疗（CCRT）可提高不可切除的局部晚期非小细胞肺癌（NSCLC）患者的总生存期（OS）。本研究旨在回顾性比较接受恩度与CCRT联合治疗的不可切除局部晚期NSCLC患者与接受CCRT治疗患者的5年生存率。
本研究纳入了有长期随访数据的初治不可切除局部晚期NSCLC患者。CCRT + 恩度组患者接受恩度加根治性CCRT治疗，CCRT组患者接受根治性CCRT治疗。对于放疗剂量≥60 Gy的患者，采用Kaplan-Meier法进行生存分析，采用Cox比例风险回归模型进行单因素分析。
CCRT + 恩度组共纳入104例参与者，CCRT组纳入89例参与者。男性患者分别为88例（84.6%）和74例（83.1%）。两组的中位随访时间分别为73.6个月（95%CI：65.6至81.7个月）和66.3个月（95%CI：52.7至79.9个月）。中位总生存期（OS）分别为29.7个月（95%CI：22.8至36.6个月）和21.3个月（95%CI：15.9至26.7个月）。
本研究表明，接受恩度与根治性CCRT联合治疗的患者的5年生存率显著优于接受根治性CCRT治疗的患者。
